Welcome to our dedicated page for Eyepoint Pharmac SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EyePoint Pharmaceuticals’ SEC filings are packed with dense ophthalmology data—think multi-phase trial outcomes, sustained-release chemistry, and milestone royalty clauses. Finding the R&D burn rate or the status of DURAVYU™ in a 300-page 10-K is challenging.
Stock Titan solves this problem. Our AI-powered summaries turn every EyePoint Pharmaceuticals SEC filing into plain English, so you can move from jargon to judgment in minutes. Whether you’re tracking an 8-K material event for trial readouts, skimming a quarterly earnings report 10-Q filing for cash runway, or reviewing proxy statement executive compensation, we deliver the context that matters.
You’ll find every form, updated in real time as they hit EDGAR:
- EyePoint Pharmaceuticals insider trading Form 4 transactions with instant alerts
- EyePoint Pharmaceuticals annual report 10-K simplified—AI highlights pivotal pipeline risks
- EyePoint Pharmaceuticals Form 4 insider transactions real-time, revealing executive sentiment
- EyePoint Pharmaceuticals earnings report filing analysis that pinpoints R&D spend trends
- EyePoint Pharmaceuticals 8-K material events explained in clear language
Use our platform to:
- Spot executive stock transactions before catalysts
- Compare quarter-over-quarter clinical expense trajectories
- Understand licensing revenue streams without combing footnotes
Stop wrestling with complex biotechnology disclosures. Start understanding EyePoint Pharmaceuticals SEC documents with AI—all in one place, always current.
EyePoint Pharmaceuticals President, CEO, and Director Jay S. Duker reported a significant insider transaction on June 23, 2025. The transaction involved the sale of 56,665 shares of common stock at $8.21 per share to the Duker Family 2024 Irrevocable Trust in exchange for a promissory note valued at $465,219.65.
Following the transaction, Duker directly owns 986 shares and indirectly holds 99,165 shares through the Family Trust. The trust is managed by Duker's spouse as trustee and benefits their children. Notably, Duker has disclaimed beneficial ownership of the trust's securities.
Key transaction details:
- Transaction was executed under code 'J' (Other)
- Sale price determined by averaging high/low trading prices on transaction date
- Transaction represents a restructuring of ownership rather than a market sale
- Filing was signed by Ron Honig as Attorney-in-Fact on June 25, 2025
EyePoint Pharmaceuticals held its 2025 Annual Meeting on June 18, with 88.4% shareholder participation (60.8M shares). Key outcomes include:
- Approved 2.9 million share increase to the 2023 Long-Term Incentive Plan with 41.3M votes in favor
- Elected nine directors to the Board, with Dr. Reginald Sanders receiving highest approval (54.5M votes)
- Approved executive compensation package with 50.7M votes in favor (92.8% approval)
- Shareholders overwhelmingly preferred annual advisory votes on executive compensation (54.2M votes)
- Ratified Deloitte & Touche LLP as independent auditor with 99.5% approval (60.5M votes)
The meeting demonstrated strong shareholder engagement and support for management proposals, with all measures passing by significant margins. The company will maintain annual say-on-pay votes in response to shareholder preference.
FAQ
What is the current stock price of Eyepoint Pharmac (EYPT)?
What is the market cap of Eyepoint Pharmac (EYPT)?
What is the core focus of EyePoint Pharmaceuticals?
How does EyePoint Pharmaceuticals generate revenue?
What are the primary therapeutic areas for the company?
What makes EyePoint's technology unique?
What is DURAVYU and its significance?
How does EyePoint Pharmaceuticals differentiate itself from competitors?
In which geographic markets does the company operate?
What type of clinical trials is the company conducting?
